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Abstract
Background: Pseudofactin II is a recently identified biosurfactant secreted by Pseudomonas fluorescens BD5, the strain
obtained from freshwater from the Arctic Archipelago of Svalbard. Pseudofactin II is a novel compound identified as
cyclic lipopeptide with a palmitic acid connected to the terminal amino group of eighth amino acid in peptide moiety.
The C-terminal carboxylic group of the last amino acid forms a lactone with the hydroxyl of Thr3.
Adhesion is the first stage of biofilm formation and the best moment for the action of antiadhesive and anti-
biofilm compounds. Adsorption of biosurfactants to a surface e.g. glass, polystyrene, silicone modifies its
hydrophobicity, interfering with the microbial adhesion and desorption processes. In this study the role and
applications of pseudofactin II as a antiadhesive compound has been investigated from medicinal and therapeutic
perspectives.
Results: Pseudofactin II lowered the adhesion to three types of surfaces (glass, polystyrene and silicone) of
bacterial strains of five species: Escherichia coli, Enterococcus faecalis, Enterococcus hirae, Staphylococcus epidermidis,
Proteus mirabilis and two Candida albicans strains. Pretreatment of a polystyrene surface with 0.5 mg/ml
pseudofactin II inhibited bacterial adhesion by 36-90% and that of C. albicans by 92-99%. The same concentration
of pseudofactin II dislodged 26-70% of preexisting biofilms grown on previously untreated surfaces. Pseudofactin II
also caused a marked inhibition of the initial adhesion of E. faecalis, E. coli, E. hirae and C. albicans strains to silicone
urethral catheters. The highest concentration tested (0.5 mg/ml) caused a total growth inhibition of S. epidermidis,
partial (18-37%) inhibition of other bacteria and 8-9% inhibition of C. albicans growth.
Conclusion: Pseudofactin II showed antiadhesive activity against several pathogenic microorganisms which are
potential biofilm formers on catheters, implants and internal prostheses. Up to 99% prevention could be achieved
by 0.5 mg/ml pseudofactin II. In addition, pseudofactin II dispersed preformed biofilms. Pseudofactin II can be used
as a disinfectant or surface coating agent against microbial colonization of different surfaces, e.g. implants or
urethral catheters.
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Background
Biofilms, which are formed by t h em a j o r i t yo fm i c r o o r -
ganisms in natural environments, are structures with
low sensitivity to drugs [1]. Many laboratories are
synthesizing or isolating new compounds preventing the
formation of biofilms or causing their elimination [2,3].
Adhesion is the first stage of biofilm formation and the
best moment for the action of antiadhesive and anti-bio-
film compounds. Biosurfactants are promising com-
pounds often showing antimicrobial and antiadhesive
properties and sometimes penetrating and removing
mature biofilms [4]. Microbial surfactants-amphiphilic,
surface-active, secondary metabolites of bacteria or fungi
ranging from low-molecular-mass glycolipids, sophoroli-
pids, rhamnolipids and lipopeptides, to high-molecular-
mass proteins, lipopolysaccharides and lipoproteins [5]-
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any medium, provided the original work is properly cited.can interact with interfaces and inhibit the adhesion of
microorganisms to different surfaces. They are an alter-
native to synthetic surface-active agents because of their
low toxicity and biodegradability [6].
Another mechanism of biosurfactant action is the per-
meabilization of bacterial cells. The rhamnolipid
secreted by Pseudomonas sp. S-17 permeabilized Gram-
negative and Gram-positive cells, but a strong inhibition
of growth was observed only in the case of Gram-posi-
tive bacteria [7]. Biofilm disruption was observed after
the addition of rhamnolipids from Pseudomonas aerugi-
nosa [8] and lipopeptide from Bacillus spp. [9]. A parti-
cular group of biosurfactants, lipopeptides, can act as
antibiotics and also as antiviral [10] and antitumor
agents [11]. Surfactin from Bacillus subtilis can interact
with the plasma membranes of bacterial and fungal cells
leading to their disruption [12]. The effects of biosurfac-
tants on decreased microbial adhesion and detachment
from different surfaces can be conveniently utilized in
many fields, from medicine to various branches of
industry, e.g., antimicrobial or antitumor activities
[13,14] and their surface activity and antiadhesive prop-
erties can be suitable for preventing microbial coloniza-
tion of implants or urethral catheters. Microbial
surfactants from Lactobacillus fermentum and Lactoba-
cillus acidophilus adsorbed on glass, reduced the num-
ber of adhering uropathogenic cells of Enterococcus
faecalis by 77% [15]. A surfactant released by Streptococ-
cus thermophilus has been used for fouling control of
heat-exchanger plates in pasteurizers as it retards the
colonization of other thermophilic strains of Streptococ-
cus responsible for fouling [16].
Within the collection of 132 morphologically distinct
bacteria isolated from water and ground provided from
the wild environment around the University of Wroclaw
scientific base in the Arctic Archipelago of Svalbard
[17], Pseudomonas fluorescens BD5 was identified as
strain which strongly reduces surface tension of its cul-
ture supernatant [18]. We purified and identified the
chemical structure of two new P. fluorescens BD5 bio-
surfactants, pseudofactin I and II [19]. Both compounds
are cyclic lipopeptides with a palmitic acid connected to
the terminal amino group of an octapeptide. The C-
terminal carboxylic group of the last amino acid (Val or
Leu) forms a lactone with the hydroxyl of Thr3. The
biosurfactant was found to be stable within the range
from -20°C to 100°C, had the minimum surface tension
(31.5 mN/m) and the critical micelle concentration (72
mg/L) [19]. Emulsification activity and stability of pseu-
dofactin II was greater than that of the synthetic surfac-
tants such as Tween 20 and Triton X-100.
The aim of this paper was to assess how the pseudo-
factin II influences the adhesion and biofilm formation
of microorganisms such as Escherichia coli, E. faecalis,
Enterococcus hirae, Staphylococcus epidermidis, Proteus
mirabilis, Vibrio ordalii, Vibrio harveyi and Candida
albicans found in gastrointestinal and urinary tract.
Since the effects of a surfactant may differ depending on
both the type of the microorganism and the type of sur-
face it adheres to, we tested its action on the adherence
of the above pathogenic microorganisms to three types
of surfaces, polystyrene, glass (as standard laboratory
surfaces for adhesion tests) and silicone (used in medical
application such as urethral catheters).
Methods
Microorganisms and culture conditions
P. fluorescens BD5 strain was obtained from freshwater
from the Arctic Archipelago of Svalbard [19] and main-
tained on the mineral salts medium MSM (7 g/L
K2HPO4,2g / LK H 2PO4,1g / L( N H 4)2SO4,0 . 5g / L
sodium citrate 2H2O, and 0.1 g/L MgSO4.7H2O) with
2% D-glucose.
The antimicrobial and antiadhesive properties of pseu-
dofactin II were tested on several pathogenic strains that
colonize animals gastrointestinal tract or medical
devices. E. coli ATCC 25922, E. coli ATCC 10536, E.
coli 17-2 (clinical isolate, Wroclaw Medical University),
E. faecalis ATCC 29212, E. faecalis JA/3 (clinical isolate,
Wroclaw Medical University), E. hirae ATCC 10541, S.
epidermidis KCTC 1917 [20], P. mirabilis ATCC 21100
were grown at 37°C and V. harveyi ATCC 14126,V .
ordalii KCCM 41669 were grown at 28°C in LB medium
(10 g/L bacto-tryptone, 5 g/L bacto-yeast extract, 10 g/L
NaCl). Two fungal strains, C. albicans ATCC 20231 and
C. albicans SC5314 [21], were grown in a 6.7 g/L yeast
nitrogen base (YNB, pH 5.5), broth (Difco Laboratories)
containing 2% D-glucose for adhesion tests. To prevent
filamentation of C. albicans, pre-culture was incubated
at 28°C, while experiments with biofilms were per-
formed at 37°C. RPMI-1640 medium (Cambrex, Ver-
viers, Belgium) was used for Candida biofilms
formation.
Isolation and purification of pseudofactin II
Pseudofactin II produced by P. fluorescens BD5 was
obtained by extraction of cell free supernatant by ethyl
acetate and evaporation of the extract under vacuum.
The crude biosurfactant was separated by RP-HPLC in
the same manner as reported earlier [19]. Purified pseu-
dofactin II fraction was dried and stored at -20°C for
further studies. Analytical RP-HPLC (data not shown) of
purified pseudofactin II showed that its purity was >
99%.
Antimicrobial assays
The antimicrobial activity of isolated pseudofactin II was
determined by the microdilution method in 96-well flat-
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many). Briefly, 50 μl volumes of sterile double strength
LB (for bacterial) or YNB (for yeast) medium were dis-
pensed into the wells of a 96-well microplate. Subse-
quently, 50 μl volumes of pseudofactin II (0.035 to 0.5
mg/ml) solution in phosphate-buffered saline (PBS)
were added to the microplate wells and mixed with the
medium. Negative and growth control wells did not
contain biosurfactant. All wells (except for negative con-
trols) were inoculated with 2 μl of overnight bacterial or
yeast cultures (diluted to OD600 =0 . 1 )i nL Bo rY N B
medium respectively, and the microplates were incu-
bated for 24 h at 37°C or 28°C for bacterial or yeast cul-
tures, respectively. After 24 h of incubation, the optical
density at 600 nm of each well was measured using an
Asys UVM 340 (Biogenet) microplate reader. The
growth inhibition percentages at different pseudofactin
II concentrations for each microorganism were calcu-
lated as:
%growth inhibition =

1 −

ODT
ODC

× 100
where ODT represents the optical density of the well
with a given pseudofactin II concentration and ODC is
the optical density of the control well (growth without
pseudofactin II). Assays were carried out three times in
three replicates.
Preadhesion treatment with pseudofactin II
Inhibition of microbial adhesion by pseudofactin II was
tested in 96-well plates (Sarstedt, Nümbrecht, Germany).
Briefly, the wells of a sterile 96-well flat-bottom plate
were filled with 100 μl of 0.035-0.5 mg/ml pseudofactin
II dissolved in PBS. The plates were incubated for 2 h at
37°C on a rotary shaker (MixMate, Eppendorf, Ham-
burg, Germany) at 300 rpm and subsequently washed
twice with PBS. Negative control (blank) wells contained
pseudofactin II at the highest concentration tested (0.5
mg/ml) while positive control wells contained PBS buf-
fer only. The overnight cultures of microbial strains
were centrifuged, washed twice with PBS (pH = 7.4) and
re-suspended in PBS to an optical density OD600 =1 . 0
for bacterial and OD600 =0 . 6f o rCandida strains. The
highest adhesion without pseudofactin II were observed
at these optical densities (data not shown). A 100 μla l i -
quot of a washed microbial suspension was added and
incubated in the wells. After a 2 h incubation at 37°C in
a rotary shaker (MixMate, Eppendorf, Hamburg, Ger-
many) at 300 rpm nonadherent cells were removed by
three washes with PBS. Then the plates were stained
with 0.1% crystal-violet for 5 min and again washed
three times with PBS. The adherent microorganisms
were permeabilized and the dye was resolubilized with
150 μlo fi s o p r o p a n o l - 0 . 0 4NH C la n d5 0μl of 0.25%
SDS per well. Crystal violet optical density readings of
each well were taken at 590 nm on the Asys UVM 340
(Biogenet) microplate. Pseudofactin II did not affect the
absorption of negative control (crystal violet in blank
wells). The microbial adhesion inhibition was calculated
as growth inhibition. Assays were carried out three
times in three replicates.
Postadhesion treatment with pseudofactin II
The 96-well flat-bottomed plates were incubated for 2 h
o nar o t a r ys h a k e r( M i x M a t e ,E p p e n d o r f ,H a m b u r g ,
Germany) at 300 rpm with 100 μl of bacterial suspen-
sion (OD600 =1 . 0 )a n dCandida suspension (OD600 =
0.6) in PBS at 37°C. Unattached microbial cells were
removed by washing the wells three times with PBS.
Next, 100 μlo f0 . 0 3 5 - 0 . 5m g / m lp s e u d o f a c t i nI Iw a s
added to each well and incubated at 37°C for 2 h on a
rotary shaker (MixMate, Eppendorf, Hamburg, Ger-
many) at 300 rpm. Control wells contained only PBS.
The plates were washed three times, adherent cells were
fixed with 100 μl of 0.1% crystal violet for 5 min and
again washed three times with PBS. The adherent
microorganisms were permeabilized and the dye was
resolubilized with 150 μl of isopropanol-0.04 N HCl and
50 μl of 0.25% SDS per well. The crystal violet optical
density of each well was measured at 590 nm using the
microplate reader. Assays were carried out three times
in three replicates. The microbial adhesion dislodging
percentages at different pseudofactin II concentrations
for each microorganism were calculated as:
%growth inhibition =

1 −

ODT
ODC

× 100
where ODT represents the optical density of the well
with a given pseudofactin II concentration and ODC the
optical density of the control well (without pseudofactin
II). Assays were carried out three times in three
replicates.
Confocal laser scanning microscopy
Confocal laser scanning microscopy (CLSM) was used
for visualizing the formation of bacterial and Candida
biofilms in the absence or presence of pseudofactin II
(final concentration 0.25 mg/ml) in the culture medium.
Bacterial and yeast biofilms were formed on Thermanox
plastic coverslips (Nalgen Nunc International Co.,
Rochester, NY), glass microscopic coverslips (Menzel-
Glaser, Germany) and segments of silicone urethral
catheters (Unomedical, Denmark) placed in wells of 24-
well plates (Nalgen Nunc International Co., Rochester,
NY) containing LB medium for bacteria and RPMI-1640
medium for yeast. Inocula were prepared as follows: 24
Janek et al. BMC Microbiology 2012, 12:24
http://www.biomedcentral.com/1471-2180/12/24
Page 3 of 9h old overnight cultures were harvested and re-sus-
pended at normalized dilutions (OD600 = 0.01). Five
hundred microliters inocula were injected into the wells
with the coverslips and incubated for 24 h at 37°C.
After this time, the coverslips were washed with PBS for
15 min. Then, the bacterial biofilms were stained for 30
min at 37°C with 1 ml of 0.6% Live/Dead BacLight via-
bility stain (Molecular Probes, Eugene, OR) dissolved in
PBS, and PBS-containing concanavalin A-Alexa Fluor
488 (Molecular Probes, Eugene, OR) conjugate (0.025
mg/ml) for Candida biofilms. The stained biofilms were
visualized by CLSM with an Olympus FluoView 500
(Olympus Optical Co. Ltd., Japan) microscope. The
CLSM used an argon ion laser at 480-490 nm for excita-
tion and a 500-635 nm band pass filter for emission.
CLSM images were processed by Olympus FluoView
500 software. Assays were carried out two times. Repre-
sentative images are presented on Figure 1.
Biofilm formation in urethral catheters
The uropathogenic strains E. coli, E. faecalis, E. hirae
and C. albicans were used in these tests. Ten microliter
volumes of overnight cultures of E. coli ATCC 25922, E.
faecalis ATCC 29212, E. hirae ATCC 10541 were added
into 1000 μl of fresh LB medium, and the same volume
of C. albicans SC5314 was added into 1000 μlo ff r e s h
RPMI-1640 medium. To the medium was added 1000 μl
pseudofactin II (final concentration 0.25 mg/ml) solu-
tion in LB medium (for bacterial) and RPMI-1640 med-
ium for C. albicans and 4 cm long segments of sterile
silicone urethral catheters (Unomedical, Denmark). The
catheters were incubated at 37°C overnight. The cultures
were removed and the catheters were washed with dis-
tilled water. After washing, 3000 μl of crystal violet
(0.1%) was added to the catheters for 20 min. The
stained biofilms were rinsed three times with distilled
water and allowed to dry at room temperature for 15
min before examination. In a parallel experiment the
catheters were pretreated with pseudofactin II by being
placed in a tube with 2000 μl of 0.25 mg/ml pseudofac-
tin II dissolved in PBS, incubated for 2 h at 37°C and
subsequently washed twice with PBS. Then the experi-
ment was carried out as in the case of adding pseudo-
factin II into the growth medium. Assays were carried
out two times. Representative images are presented on
Figure 2. This experiment was carried out under
dynamic conditions using a peristaltic pump, where the
flow of culture with or without pseudofactin II trough
urethral catheters was 50 ml/h.
Results and discussion
Antimicrobial activity of pseudofactin II
Lipopeptides have typical amphiphilic structure of a sur-
factant, where the hydrophobic moiety is a hydroxyl or
a-alkyl-b-hydroxy fatty acid (e.g. 3-OH-C14,3 - O H - C 15
and 3-OH-C10 fatty acids) and the hydrophilic moiety is
a short chain or a cyclic peptide [22,23]. Instead, the
hydrophobic moiety of pseudofactin II contains palmitic
acid, which is a saturated fatty acid having no hydroxyl
group. Rhodofactin, another lipopeptide with palmitic
acid, has been described by Peng et al. [24]; however,
contrary to pseudofactin II it has a short peptide chain
which does not form lactone ring. Its antimicrobial
activity has not yet been described.
The antimicrobial activity of pseudofactin II isolated
from P. fluorescens BD5 was evaluated at concentrations
from 0.035 to 0.5 mg/ml (Table 1). At 0.5 mg/ml the
agent caused a total growth inhibition of S. epidermidis
KCTC 1917 and considerable growth inhibition of P.
mirabilis ATCC 21100 (37%), E. coli ATCC 10536 and
E. coli 17-2 (32%), E. hirae ATCC 10541 (28%).
In contrast to surfactin or iturin, produced by B. sub-
tilis [25,26], lichenysin from Bacillus licheniformis [27]
or polymyxin B and E from Bacillus polymyxa [28],
pseudofactin II showed much weaker dose dependent
antimicrobial activity against most strains tested in this
work (Table 1). Only for two Vibrio strains pseudofactin
II completely inhibited the growth in the lowest tested
concentration, thus they were not used in further
experiments (data not shown). This may be due to its
unique chemical structure different from any currently
known lipopeptides, which features a hydrophobic alkyl
chain without a hydroxyl moiety attached to cyclic
peptide.
Antiadhesive and cell-dislodging activity of pseudofactin
II on polystyrene surfaces
Adhesion of pathogenic microorganisms to solid sur-
faces or to infection sites has been found to be inhibited
by biosurfactants capable of modifying the physico-che-
mical properties of the surface to reduce adhesion and
biofilm formation on a given biomaterial.
Pseudofactin II was found to possess antiadhesive
activity against all tested microorganisms. The pretreat-
ment of polystyrene surfaces with pseudofactin II signifi-
cantly decreased the adhesion of all bacteria and yeast,
and this antiadhesive effect was concentration-depen-
dent (Table 2). The highest reduction of adhesion (80-
99%) was observed for C. albicans SC 5314, C. albicans
ATCC 20231, P. mirabilis ATCC 21100 and E. coli
ATCC 10536. The dislodging effect of pseudofactin II
on preformed biofilms on untreated surfaces was lower
than the preventive effect of pretreatment and was in
the range of 26-70% for 0.5 mg/ml pseudofactin II
(Table 3).
The adhesion of pathogenic bacteria to polystyrene
surfaces was inhibited by two lipopeptide biosurfactants
produced by B. subtilis and B. licheniformis [9], and
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Figure 1 Confocal scanning laser microscopy images of biofilm formation on polystyrene, glass microscopic coverslips and cut
fragment of silicone urethral catheters by different bacterial strains: ((A, I, R) Escherichia coli ATCC 25922, (B, J, S) Enterococcus
faecalis ATCC 29212, (C, K, T) Enterococcus hirae ATCC 10541, (D, L, U) Candida albicans SC5314) and biofilm inhibition after
incubation with pseudofactin II (0.25 mg/ml) in the culture medium: (E, M, W) Escherichia coli ATCC 25922, (F, N, X) Enterococcus
faecalis ATCC 29212, (G, O, Y) Enterococcus hirae ATCC 10541, (H, P, Z) Candida albicans mμSC5314). Scale bars: 50 μl.
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Figure 2 Pseudofactin II inhibits biofilm formation on silicone urethral catheters. The organisms were grown overnight at 37°C in a test-
tube with sterile urethral catheters containing medium (A) with and without 0.25 mg/ml pseudofactin II and (B) where the urethral catheters
was pre-incubated with biosurfactant at concentration 0.25 mg/ml as described in the text. Biofilms were visualized by staining with crystal
violet.
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microplates was reduced by 84% on pretreating the sur-
face with surfactin (1 mg/ml), and by 82% when it was
treated with purified rhamnolipid (7.5 mg/ml) [29].
Gudina et al. [30] characterized the anti-adhesive activ-
ity of biosurfactants against several microorganisms
including Gram-positive and Gram-negative bacteria.
This biosurfactant at concentration 25 mg/ml showed
high anti-adhesive activity against Staphylococcus aureus
(72.0%), S. epidermidis (62.1%), Streptococcus agalactiae
(60.0%) and low anti-adhesive activity against P. aerugi-
nosa (16.5%) and E. coli (11.5%).
Coating with pseudofactin II was effective above criti-
cal micelle concentration (0.072 mg/ml) [19]. Our
results suggest that when the surface is covered by pseu-
dofactin II micelles attached to polystyrene by van der
Waals forces, the adhesion is inhibited more strongly
than it is with monomers.
Pseudofactin II reduces biofilm formation on polystyrene,
glass and silicone
B i o f i l m sa r ed e f i n e da sm i c r o o r g a n i s m sa t t a c h e dt oa
diverse range of biotic and abiotic surfaces and prolifer-
ating on them. The human body and medical devices or
implants including: urinary catheters, voice prostheses,
orthopedic implants, ocular prostheses and contact
lenses are exposed to adhesion and biofilm formation by
many opportunistic microorganisms. Thus we have
tested the influence of pseudofactin II on biofilm forma-
tion on different materials.
The activity of pseudofactin II against biofilm forma-
tion was visualized by confocal laser scanning micro-
scopy (Figure 1). The biofilm growth of E. coli, E.
f a e c a l i s ,E .h i r a eand C. albicans on polystyrene, glass
and silicone from urethral catheters is shown in Figures
1A-D, 1I-L and 1R-U, respectively. The biosurfactant
inhibited biofilm formation at the concentration 0.25
Table 1 Growth inhibition obtained with the pseudofactin II isolated from P.fluorescens BD5 at different
concentrations (mg/ml). Values ± confidence interval, n = 9
Microorganism Growth inhibition (%)
Pseudofactin II concentration (mg/ml)
0.500 0.250 0.200 0.150 0.075 0.035
Escherichia coli ATCC 25922 8 ± 0.26 7 ± 0.52 6 ± 0.26 5 ± 0.39 3 ± 0.20 0 ± 0.26
Escherichia coli ATCC 10536 32 ± 0.26 28 ± 0.26 27 ± 0.39 18 ± 0.46 2 ± 0.26 2 ± 0.39
Escherichia coli 17-2 32 ± 0.46 29 ± 0.33 24 ± 0.20 19 ± 0.20 14 ± 0.20 6 ± 0.20
Enterococcus faecalis ATCC 29212 18 ± 0.07 13 ± 0.07 11 ± 0.07 5 ± 0.13 5 ± 0.13 2 ± 0.07
Enterococcus faecalis JA/3 18 ± 0.07 15 ± 0.07 8 ± 0.07 4 ± 0.07 3 ± 0.07 0 ± 0.07
Enterococcus hirae ATCC 10541 28 ± 0.26 25 ± 0.33 22 ± 0.13 21 ± 0.46 10 ± 0.13 5 ± 0.52
Staphylococcus epidermidis KCTC 1917 100 ± 0.07 49 ± 0.07 44 ± 0.39 42 ± 0.20 16 ± 0.33 4 ± 0.26
Proteus mirabilis ATCC 21100 37 ± 0.33 36 ± 0.20 20 ± 0.20 17 ± 0.39 13 ± 0.13 0 ± 0.39
Candida albicans ATCC 20231 18 ± 0.26 17 ± 0.39 15 ± 0.46 15 ± 0.13 14 ± 0.26 11 ± 0.20
Candida albicans SC5314 9 ± 0.07 7 ± 0.07 5 ± 0.20 4 ± 0.213 1 ± 0.07 0 ± 0.07
Table 2 Microbial adhesion inhibition in the microtiter plate by purified pseudofactin II.
Microorganism Microbial adhesion inhibition (%)
Pseudofactin II concentration (mg/ml) Control (PBS)
0.500 0.35 0.250 0.200 0.150 0.075 0.035 0
Escherichia coli ATCC 25922 66 ± 0.13 65 ± 0.13 65 ± 0.07 64 ± 0.07 62 ± 0.07 58 ± 0.07 55 ± 0.20 0
Escherichia coli ATCC 10536 80 ± 0.13 80 ± 0.13 80 ± 0.13 77 ± 0.13 72 ± 0.13 65 ± 0.07 39 ± 0.13 0
Escherichia coli 17-2 72 ± 0.33 71 ± 0.13 71 ± 0.13 69 ± 0.13 68 ± 0.07 64 ± 0.07 64 ± 0.13 0
Enterococcus faecalis ATCC 29212 70 ± 0.20 68 ± 0.20 68 ± 0.13 57 ± 0.13 55 ± 0.07 54 ± 0.07 42 ± 0.13 0
Enterococcus faecalis JA/3 36 ± 0.13 36 ± 0.13 34 ± 0.13 31 ± 0.13 22 ± 0.13 18 ± 0.20 15 ± 0.07 0
Enterococcus hirae ATCC 10541 71 ± 0.07 71 ± 0.20 71 ± 0.20 67 ± 0.20 66 ± 0.13 61 ± 0.07 58 ± 0.13 0
Staphylococcus epidermidis KCTC 1917 55 ± 0.13 45 ± 0.07 45 ± 0.07 33 ± 0.13 32 ± 0.07 31 ± 0.13 29 ± 0.13 0
Proteus mirabilis ATCC 21100 90 ± 0.20 90 ± 0.33 90 ± 0.33 89 ± 0.13 87 ± 0.07 85 ± 0.20 84 ± 0.20 0
Candida albicans ATCC 20231 92 ± 0.07 89 ± 0.07 81 ± 0.07 71 ± 0.13 68 ± 0.07 47 ± 0.20 45 ± 0.20 0
Candida albicans SC5314 99 ± 0.07 98 ± 0.07 98 ± 0.07 97 ± 0.07 96 ± 0.07 88 ± 0.07 87 ± 0.07 0
PBS was used as control and set at 0% as no microbial inhibition occurs. Values ± confidence interval, n = 9
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ures 1E-H, 1M-P and 1W-Z). E. faecalis ATCC 29212
adhesion to all tested surfaces is less intensive than
others strains (Figures 1B, J, S). In fact, the adhesion of
this strain to 96 wells plate was between 2 to 4-fold
weaker than others tested bacterial strains (data not
shown). This effect may be due to small amount of
adhesion proteins on E. faecalis ATCC 29212 strain.
Pseudofactin in the tested concentration inhibited mixed
biofilm formation (data not shown), similarly as for the
single strain (Figure 1). In our experiments all the tested
Gram-negative and Gram-positive bacteria showed
decrease of adhesion. The results of the present study
indicate that pseudofactin II have potential to be used
for efficient removal and inhibition of biofilms for
pathogenic microorganisms.
Rivardo et al. [9] demonstrated that biosurfactants
obtained from Bacillus spp. were able to inhibit biofilm
formation for two pathogenic strains E. coli at 97% and S.
aureus at 90%, respectively. Irie et al. [31] demonstrated
that rhamnolipids produced by P. aeruginosa were able
to disperse biofilm for Bordetella bronchiseptica.
Pseudofactin II prevents biofilm formation in urethral
catheters
To test biofilm formation on medical device, silicone
urethral catheters, 4 cm segments of the catheters were
incubated with E. coli ATCC 25922, E. faecalis ATCC
29212, E. hirae ATCC 10541 and C. albicans SC 5314.
E. coli, E. faecalis and E. hirae formed biofilms mainly
at the air-liquid interface, while the biofilm formed by
C. albicans was dispersed along the whole growth sur-
face (Figure 2). Even though the pseudofactin II present
in the growth medium (Figure 2A), was at the concen-
tration of 0.25 mg/ml which did not significantly affect
the growth of the tested microbial cultures, biofilm
formation was nearly completely prevented. The pre-
treatment of silicone urethral catheters with pseudofac-
tin II prior to inoculation with medium was just as
effective as including the biosurfactant in the growth
medium (Figure 2B). We observed the similar effect in
dynamic conditions for urethral catheters using a flow
of 50 ml/h (data not shown).
Earlier reports noted an inhibition of biofilms formed
by several microorganisms, e.g. Salmonella typhimur-
ium, S. enterica, E. coli and P. mirabilis on vinyl urethral
catheters by a surfactin produced by B. subtilis [32].
Our results show that pseudofactin II is promising
compound for inhibition and disruption of biofilms and
has potential applications in medicine.
Conclusions
The biosurfactant pseudofactin II, produced by P. fluores-
cens BD5 strain and purified by HPLC, showed antiadhe-
sive activity against several pathogenic microorganisms,
such as E. coli, E. faecalis, E. hirae, S. epidermidis, P. mir-
abilis and C. albicans, which are potential biofilm for-
mers on catheters, implants and internal prostheses. Up
to 99% prevention of C. albicans SC 5314 adhesion could
be achieved by 0.5 mg/ml pseudofactin II. Confocal laser
scanning microscopy confirmed the action of pseudofac-
tin II as an inhibitor of biofilm formation. In addition,
pseudofactin II dispersed preformed biofilms. Due to its
surface tension properties and lack of hemolytic activity
(data not shown), pseudofactin II can be used as a surface
coating agent against microbial colonization of different
surfaces, e.g. implants or urethral catheters.
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Table 3 Activity of cell dislodging in the microtiter plate by pseudofactin II.
Microorganism Microbial adhesion dislodging (%)
Pseudofactin II concentration (mg/ml) Control (PBS)
0.500 0.35 0.250 0.200 0.150 0.075 0.035 0
Escherichia coli ATCC 25922 66 ± 0.07 62 ± 0.07 62 ± 0.13 55 ± 0.07 42 ± 0.20 7 ± 0.07 4 ± 0.07 0
Escherichia coli ATCC 10536 64 ± 0.07 62 ± 0.13 61 ± 0.13 58 ± 0.07 50 ± 0.07 41 ± 0.07 38 ± 0.13 0
Escherichia coli 17-2 70 ± 0.13 65 ± 0.13 59 ± 0.13 51 ± 0.07 46 ± 0.13 27 ± 0.07 18 ± 0.07 0
Enterococcus faecalis ATCC 29212 48 ± 0.07 42 ± 0.13 35 ± 0.13 33 ± 0.13 23 ± 0.13 20 ± 0.13 10 ± 0.07 0
Enterococcus faecalis JA/3 26 ± 0.26 23 ± 0.26 16 ± 0.26 15 ± 0.13 10 ± 0.07 6 ± 0.07 4 ± 0.20 0
Enterococcus hirae ATCC 10541 45 ± 0.13 43 ± 0.13 41 ± 0.33 35 ± 0.20 32 ± 0.20 31 ± 0.07 25 ± 0.13 0
Staphylococcus epidermidis KCTC 1917 43 ± 0.07 39 ± 0.26 37 ± 0.07 36 ± 0.07 23 ± 0.13 20 ± 0.13 17 ± 0.26 0
Proteus mirabilis ATCC 21100 45 ± 0.26 42 ± 0.26 40 ± 0.13 34 ± 0.13 28 ± 0.07 24 ± 0.07 21 ± 0.07 0
Candida albicans ATCC 20231 29 ± 0.26 22 ± 0.07 21 ± 0.07 16 ± 0.07 11 ± 0.07 6 ± 0.07 3 ± 0.07 0
Candida albicans SC5314 39 ± 0.07 31 ± 0.07 24 ± 0.13 20 ± 0.13 17 ± 0.07 7 ± 0.13 6 ± 0.13 0
Negative controls (PBS) were set at 0%. Values ± confidence interval, n = 9
Janek et al. BMC Microbiology 2012, 12:24
http://www.biomedcentral.com/1471-2180/12/24
Page 8 of 9Author details
1Faculty of Biotechnology, University of Wroclaw, Przybyszewskiego 63/77,
Wroclaw 51-148, Poland.
2Faculty of Chemistry, Wroclaw University of
Technology, Gdańska 9/7, Wroclaw 50-344, Poland.
Authors’ contributions
TJ carried out experiments, ML participated in the design of the study, data
analysis, coordination and helped to draft the manuscript, AK conceived the
experiments and draft the manuscript. All authors read and approved the
final manuscript.
Received: 16 September 2011 Accepted: 23 February 2012
Published: 23 February 2012
References
1. Nikolaev I, Plakunov VK: Biofilm-"City of microbes” or an analogue of
multicellular organisms? Microbiologia 2007, 76:149-163.
2. Vediyappan G, Rossignol T: d’Enfert C: Interaction of Candida albicans
biofilms with antifungals: transcriptional response and binding of
antifungals to beta-glucans. Antimicrob Agents Chemother 2010,
54:2096-2111.
3. Zhao T, Liu Y: N-acetylcysteine inhibit biofilms produced by
Pseudomonas aeruginosa. BMC Microbiology 2010, 10:140.
4. Das P, Mukherjee S, Sen R: Antiadhesive action of a marine microbial
surfactant. Colloids and Surfaces B: Biointerfaces 2009, 71:183-186.
5. Rosenberg E, Ron EZ: High- and low-molecular-mass microbial
surfactants. Appl Microbiol Biotechnol 1999, 52:154-162.
6. Mukherjee S, Das P, Sen R: Towards commercial production of microbial
surfactants. Trends Biotechnol 2006, 24:509-515.
7. Sotirova AV, Spasova DI, Galabova DN, Karpenko E, Shulga A: Rhamnolipid-
biosurfactant permeabilizing effects on Gram-positive and Gram-
negative bacterial strains. Curr Microbiol 2008, 56:639-644.
8. Dusane DH, Nancharaiah YV, Zinjarde SS, Venugopalan VP: Rhamnolipid
mediated disruption of marine Bacillus pumilus biofilms. Colloids and
Surfaces B: Biointerfaces 2010, 81:242-248.
9. Rivardo F, Turner RJ, Allegrone G, Ceri H, Martinotti MG: Anti-adhesion
activity of two biosurfactants produced by Bacillus spp. prevents biofilm
formation of human bacterial pathogens. Appl Microbiol Biotechnol 2009,
83:541-553.
10. Huang X, Lu Z, Zhao H, Bie X, Lü FX, Yang S: Antiviral activity of
antimicrobial lipopeptide from Bacillus subtilis fmbj against pseudorabies
virus, porcine parvovirus, newcastle disease virus and infectious bursal
disease virus in vitro. Int J Pept Res Ther 2006, 12:373-377.
11. Rodrigues L, Banat IM, Teixeira J, Oliveira R: Biosurfactants: potential
applications in medicine. J Antimicrob Chemother 2006, 57:609-618.
12. Vollenbroich D, Pauli G, Ozel M, Vater J: Antimycoplasma properties and
application in cell culture of surfactin, a lipopeptide antibiotic from
Bacillus subtilis. Appl Environ Microbiol 1997, 63:44-49.
13. Banat IM, Makkar RS, Cameotra SS: Potential commercial applications of
microbial surfactants. Appl Microbiol Biotechnol 2000, 53:495-508.
14. Singh P, Cameotra SS: Potential applications of microbial surfactants in
biomedical sciences. Trends Biotechnol 2004, 22:142-146.
15. Velraeds MMC, van der Mei HC, Reid G, Busscher HJ: Inhibition of initial
adhesion of uropathogenic Enterococcus faecalis by biosurfactants from
Lactobacillus isolates. Appl Environ Microbiol 1996, 62:1958-1963.
16. Busscher HJ, van der Kuij-Booij M, van der Mei HC: Biosurfactants from
thermophilic dairy streptococci and their potential role in the fouling
control of heat exchanger plates. J Ind Microbiol Biotechnol 1996, 16:15-21.
17. Krasowska A, Łukaszewicz M: Isolation, identification of Arctic
microorganisms, and their proteolytic and lipolytic activity (Izolacja,
identyfikacja oraz aktywność proteolityczna i lipolityczna
mikroorganizmów arktycznych). Acta Sci Pol Biotech 2011, 10:3-12 [http://
www.aqua.ar.wroc.pl/acta/pl/full/3/2011/000030201100010000010000500014.
pdf].
18. Krasowska A, Dąbrowska B, Łukaszewicz M: Isolation and characterization
of microorganisms from Arctic archipelago of Svalbard. J Biotechnol 2007,
131:S240.
19. Janek T, Łukaszewicz M, Rezanka T, Krasowska A: Isolation and
characterization of two new lipopeptide biosurfactants produced by
Pseudomonas fluorescens BD5 isolated from water from the Arctic
Archipelago of Svalbard. Bioresource Technol 2010, 101:6118-6123.
20. Kim KM, Lee JY, Kim CK, Kang JS: Isolation and characterization of
surfactin produced by Bacillus polyfermenticus KJS-2. Arch Pharm Res
2009, 32:711-715.
21. Gillum AM, Tsay EY, Kirsch DR: Isolation of the Candida albicans gene for
orotidine-50-phosphate decarboxylase by complementation of S.
cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984,
198:179-182.
22. Laycock M, Hildebrand PD, Thibault P, Walter JA, Wright JLC: Viscosin, a
potent peptidolipid biosurfactant and phytopathogenic mediator
produced by a pectolytic strain of Pseudomonas fluorescens. J Agr Food
Chem 1991, 39:483-489.
23. Youssef NH, Duncan KE, McInerney MJ: Importance of 3-hydroxy fatty acid
composition of lipopeptides for biosurfactant activity. Appl Environ
Microbiol 2005, 71:7690-7695.
24. Peng F, Wang Y, Sun F, Liu Z, Lai Q, Shao Z: A novel lipopepitide
produced by a Pacific Ocean deep-sea bacterium, Rhodococcus sp.
TW53. J Appl Microbiol 2008, 105:698-705.
25. Peypoux F, Bonmatin JM, Wallach J: Recent trends in the biochemistry of
surfactin. Appl Microbiol Biotechnol 1999, 51:553-563.
26. Besson F, Peypoux F, Michel G, Delcambe L: Characterization of iturin A in
antibiotics from various strains of Bacillus subtilis. J Antibiot 1976,
29:1043-1049.
27. Grangemard I, Wallach J, Maget-Dana R, Peypoux F: Lichenysin: a more
efficient cation chelator than surfactin. Appl Biochem Biotechnol 2001,
90:199-210.
28. Landman D, Georgescu C, Martin DA, Quale J: Polymyxins revisited. Clin
Microbiol Rev 2008, 21:449-465.
29. De Araujo LV, Abreu F, Lins U, de Melo Santa Anna LM, Nitschke M, D
Guimarăes Freire DM: Rhamnolipid and surfactin inhibit Listeria
monocytogenes adhesion. Food Research International 2011, 44:481-488.
30. Gudińa EJ, Teixeira JA, Rodrigues LR: Isolation and functional
characterization of a biosurfactant produced by Lactobacillus paracasei.
Colloids Surf B 2010, 76:298-304.
31. Irie Y, O’Toole GA, Yuk MH: Pseudomonas aeruginosa rhamnolipids
disperse Bordetella bronchiseptica biofilms. FEMS Microbiology Lett 2005,
250:237-243.
32. Mireles JR, Toguchi A, Harshey RM: Salmonella enterica serovar
Typhimurium swarming mutants with altered biofilm-forming abilities:
surfactin inhibits biofilm formation. J Bacteriol 2001, 183:5848-5854.
doi:10.1186/1471-2180-12-24
Cite this article as: Janek et al.: Antiadhesive activity of the
biosurfactant pseudofactin II secreted by the Arctic bacterium
Pseudomonas fluorescens BD5. BMC Microbiology 2012 12:24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Janek et al. BMC Microbiology 2012, 12:24
http://www.biomedcentral.com/1471-2180/12/24
Page 9 of 9